Novo Nordisk Wegovy Hits 3M U.S. Prescriptions in 22 Weeks
Has Novo Nordisk Wegovy just delivered the prescription surge that forces Wall Street to rethink the entire obesity trade? Maik Kemper Editor in Chief The oral Wegovy tablet…
Novo Nordisk Wegovy Faces a Warning in the Obesity Race
Can Novo Nordisk Wegovy regain momentum fast enough to challenge Eli Lilly before the next wave of obesity drugs resets the market? Maik Kemper Editor in Chief Oral…
Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s sales? Maik Kemper Editor in Chief With the…
Novo Nordisk ADA +2.3%: CagriSema Data Back in Focus
Can Novo Nordisk ADA data finally give investors a reason to believe the GLP-1 leader can regain momentum? Maik Kemper Editor in Chief The conference highlights the strength…
Novo Nordisk FDA Compounding +4.8% Surge Shakes GLP‑1 Rivals
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom? Maik Kemper Editor in Chief When FDA‑approved drugs are…
Novo Nordisk GLP-1 competition Warning with new pill rival
Can Novo Nordisk defend its GLP-1 dominance as a potent oral rival emerges and a bold US telehealth deal reshapes distribution? How does Structure Therapeutics challenge Novo Nordisk?…